Molecular mechanisms of PD-1 immune checkpoint inhibitors in mouse mammary tumours
RNA-seq (gene expression) · mouse · 20 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 20 samples: 5 × Control vs 5 × Control + anti-PD-1 vs 5 × Letrozole vs 5 × Letrozole + anti-PD-1Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE268752_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1118676 and SRA study SRP510989. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 20 samples.
How we read this: 4 replicated groups read from 20 sample titles; they account for 20 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8298412 Control rep 1 Control
- GSM8298413 Control rep 2 Control
- GSM8298414 Control rep 3 Control
- GSM8298415 Control rep 4 Control
- GSM8298416 Control rep 5 Control
- GSM8298417 Control + anti-PD-1 rep 1 Control + anti-PD-1
- GSM8298418 Control + anti-PD-1 rep 2 Control + anti-PD-1
- GSM8298419 Control + anti-PD-1 rep 3 Control + anti-PD-1
- GSM8298420 Control + anti-PD-1 rep 4 Control + anti-PD-1
- GSM8298421 Control + anti-PD-1 rep 5 Control + anti-PD-1
- GSM8298422 Letrozole rep 1 Letrozole
- GSM8298423 Letrozole rep 2 Letrozole
- GSM8298424 Letrozole rep 3 Letrozole
- GSM8298425 Letrozole rep 4 Letrozole
- GSM8298426 Letrozole rep 5 Letrozole
- GSM8298427 Letrozole + anti-PD-1 rep 1 Letrozole + anti-PD-1
- GSM8298428 Letrozole + anti-PD-1 rep 2 Letrozole + anti-PD-1
- GSM8298429 Letrozole + anti-PD-1 rep 3 Letrozole + anti-PD-1
- GSM8298430 Letrozole + anti-PD-1 rep 4 Letrozole + anti-PD-1
- GSM8298431 Letrozole + anti-PD-1 rep 5 Letrozole + anti-PD-1
- GSE293295 Discovery of BMS-986408, a First-In-Class Dual DGK⍺ and DGK Inhibitor That Unleashes PD-1 Checkpoint and CAR-T Cell Immunotherapies 20 samples shares pd-1, checkpoint
- GSE337208 scRNA seq. of PDAC models treated with Kras inhibitors in combination with checkpoint immunotherapy 9 samples shares checkpoint, inhibitors
- GSE327494 Localized PD-1 CAR T therapy reprograms neuroinflammation - mouse CAR T data. 302 samples shares pd-1
- GSE334585 iNOS is a key mediator of anti-PD-1 melanoma therapy response 48 samples shares pd-1
- GSE317833 PD-1 Deficiency Exacerbates Mycobacterium abscessus Lung Infection via Dysregulated T Cell Responses 30 samples shares pd-1
- GSE292614 Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy [scRNAseq] 24 samples shares pd-1
- GSE261642 PLPP1-deficiency-mediated ferroptosis induced by PD-1 signaling impairs antitumor activity of intratumoral CD8+ T cells I 23 samples shares pd-1
- GSE290839 PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and cell-extrinsic fashion [scRNA-seq] 20 samples shares pd-1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.